Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy

Cell Reports

Volumn 17, Issue 10, 2016, Pages 2503-2511

  Tzeng, Alice ^a,b   Kauke, Monique J ^a,b   Zhu, Eric F ^a,b   Moynihan, Kelly D ^a,b   Opel, Cary F ^a,b   Yang, Nicole J ^a,b   Mehta, Naveen ^a,b   Kelly, Ryan L ^a,b   Szeto, Gregory L ^d   Overwijk, Willem W ^e   Irvine, Darrell J ^a,b,c   Wittrup, K Dane ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d Baltimore County   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

cytokines; DC maturation; schedule dependent synergy; timing

Indexed keywords

ALPHA INTERFERON; CANCER ANTIBODY; CD8ALPHA ANTIGEN; INTERLEUKIN 2; TA 99 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8 ALPHA DENDRITIC CELL; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL MELANOMA; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PATHOLOGY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE;

EID: 85002688614     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.11.020     Document Type: Article

References (29)

1. Barouch, D.H., Santra, S., Steenbeke, T.D., Zheng, X.X., Perry, H.C., Davies, M.E., Freed, D.C., Craiu, A., Strom, T.B., Shiver, J.W., Letvin, N.L., Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J. Immunol. 161 (1998), 1875–1882.
2. Bezu, L., Gomes-de-Silva, L.C., Dewitte, H., Breckpot, K., Fucikova, J., Spisek, R., Galluzzi, L., Kepp, O., Kroemer, G., Combinatorial strategies for the induction of immunogenic cell death. Front. Immunol., 6, 2015, 187.
3. Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
4. Cohen, S.M., Kaufman, H.L., Combination cytokine therapy. Caligiuri, M.A., Lotze, M.T., (eds.) Cytokines in the Genesis and Treatment of Cancer, 2007, Humana Press, 373–398.
5. Corrales, L., Glickman, L.H., McWhirter, S.M., Kanne, D.B., Sivick, K.E., Katibah, G.E., Woo, S.R., Lemmens, E., Banda, T., Leong, J.J., et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11 (2015), 1018–1030.
6. den Haan, J.M., Bevan, M.J., Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(−) dendritic cells in vivo. J. Exp. Med. 196 (2002), 817–827.
7. Diamond, M.S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G.P., Archambault, J.M., Lee, H., Arthur, C.D., White, J.M., Kalinke, U., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208 (2011), 1989–2003.
8. Draganov, D., Gopalakrishna-Pillai, S., Chen, Y.R., Zuckerman, N., Moeller, S., Wang, C., Ann, D., Lee, P.P., Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death. Sci. Rep., 5, 2015, 16222.
9. Ferlazzo, G., Pack, M., Thomas, D., Paludan, C., Schmid, D., Strowig, T., Bougras, G., Muller, W.A., Moretta, L., Münz, C., Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl. Acad. Sci. USA 101 (2004), 16606–16611.
10. Fuertes, M.B., Kacha, A.K., Kline, J., Woo, S.R., Kranz, D.M., Murphy, K.M., Gajewski, T.F., Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 208 (2011), 2005–2016.
11. Fuertes, M.B., Woo, S.R., Burnett, B., Fu, Y.X., Gajewski, T.F., Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34 (2013), 67–73.
12. Fujii, S., Shimizu, K., Smith, C., Bonifaz, L., Steinman, R.M., Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198 (2003), 267–279.
13. Haque, A., Best, S.E., Montes de Oca, M., James, K.R., Ammerdorffer, A., Edwards, C.L., de Labastida Rivera, F., Amante, F.H., Bunn, P.T., Sheel, M., et al. Type I IFN signaling in CD8- DCs impairs Th1-dependent malaria immunity. J. Clin. Invest. 124 (2014), 2483–2496.
14. Hennessy, E.J., Parker, A.E., O'Neill, L.A., Targeting Toll-like receptors: emerging therapeutics?. Nat. Rev. Drug Discov. 9 (2010), 293–307.
15. Lu, Y.C., Yao, X., Crystal, J.S., Li, Y.F., El-Gamil, M., Gross, C., Davis, L., Dudley, M.E., Yang, J.C., Samuels, Y., et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin. Cancer Res. 20 (2014), 3401–3410.
16. Luft, T., Pang, K.C., Thomas, E., Hertzog, P., Hart, D.N.J., Trapani, J., Cebon, J., Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 161 (1998), 1947–1953.
17. Matsushita, H., Vesely, M.D., Koboldt, D.C., Rickert, C.G., Uppaluri, R., Magrini, V.J., Arthur, C.D., White, J.M., Chen, Y.S., Shea, L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482 (2012), 400–404.
18. Melero, I., Berman, D.M., Aznar, M.A., Korman, A.J., Pérez Gracia, J.L., Haanen, J., Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15 (2015), 457–472.
19. Overwijk, W.W., Restifo, N.P., B16 as a mouse model for human melanoma. Curr. Protoc. Immunol., 20, 2001, 20.1.
20. Park, S., Jiang, Z., Mortenson, E.D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N.K., Greene, M., et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18 (2010), 160–170.
21. Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Lu, H., Cuillerot, J.-M., Lynch, T.J., Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann. Oncol. 24 (2013), 75–83.
22. Schwartz, S.A., Morgenstern, B., Capizzi, R.L., Schedule-dependent synergy and antagonism between high-dose 1-β-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia. Cancer Res. 42 (1982), 2191–2197.
23. Sckisel, G.D., Bouchlaka, M.N., Monjazeb, A.M., Crittenden, M., Curti, B.D., Wilkins, D.E., Alderson, K.A., Sungur, C.M., Ames, E., Mirsoian, A., et al. Out-of-sequence signal 3 paralyzes primary CD4(+) T-cell-dependent immunity. Immunity 43 (2015), 240–250.
24. Sikora, A.G., Jaffarzad, N., Hailemichael, Y., Gelbard, A., Stonier, S.W., Schluns, K.S., Frasca, L., Lou, Y., Liu, C., Andersson, H.A., et al. IFN-α enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J. Immunol. 182 (2009), 7398–7407.
25. Stagg, J., Loi, S., Divisekera, U., Ngiow, S.F., Duret, H., Yagita, H., Teng, M.W., Smyth, M.J., Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl. Acad. Sci. USA 108 (2011), 7142–7147.
26. White, A.L., Chan, H.T.C., Roghanian, A., French, R.R., Mockridge, C.I., Tutt, A.L., Dixon, S.V., Ajona, D., Verbeek, J.S., Al-Shamkhani, A., et al. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187 (2011), 1754–1763.
27. Wilson, N.S., Behrens, G.M., Lundie, R.J., Smith, C.M., Waithman, J., Young, L., Forehan, S.P., Mount, A., Steptoe, R.J., Shortman, K.D., et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 7 (2006), 165–172.
28. Yang, H., Yamazaki, T., Pietrocola, F., Zhou, H., Zitvogel, L., Ma, Y., Kroemer, G., STAT3 inhibition enhances the therapeutic efficacy of immunogenic chemotherapy by stimulating type 1 interferon production by cancer cells. Cancer Res. 75 (2015), 3812–3822.
29. Zhu, E.F., Gai, S.A., Opel, C.F., Kwan, B.H., Surana, R., Mihm, M.C., Kauke, M.J., Moynihan, K.D., Angelini, A., Williams, R.T., et al. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell 27 (2015), 489–501.